Perspectives

Know Your Guidelines Series: The CDC Clinical Practice Guideline for Prescribing Opioids for Pain

Authors: Margaux Meilhac, BS, Suzanne Nesbit, PharmD, Lindsay A. Bowman, PharmD, Rosalyn W. Stewart, MD, MS, MBA

Abstract

As a symptom of many diseases and a chronic condition in its own right, pain is a nearly universal experience. Although prescription opioids are effective in treating some types of pain, they carry the risk of misuse or abuse due to their addictive potential.1

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015;156:5692013;576.
 
2. Centers for Disease Control and Prevention. CDC releases updated Clinical Practice Guideline for prescribing opioids for pain. https://www.cdc.gov/media/releases/2022/p1103-Prescribing-Opioids.html. Published November 3, 2022. Accessed December 8, 2022.
 
3. Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med 2019;380:22852013;2287.
 
4. Centers for Disease Control and Prevention. CDC Clinical Practice Guideline for prescribing opioids for pain – United States, 2022. https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1_w. Published November 3, 2022. Accessed December 8, 2022.
 
5. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Opioid prescribing resources. https://www.cdc.gov/opioids/healthcareprofessionals/prescribing/index.html. Accessed November 28, 2023.
 
6. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Training for healthcare professionals. https://www.cdc.gov/overdose-prevention/hcp/trainings/?CDC_AAref_Val=https://www.cdc.gov/opioids/healthcare-professionals/training/index.html. Accessed November 28, 2023.
 
7. Centers for Disease Control and Prevention. Checklist for prescribing opioids for chronic pain. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/?CDC_AAref_Val=https://www.cdc.gov/drugoverdose/pdf/pdo_checklist-a.pdf. Accessed November 28, 2023.
 
8. Ahmed F. US Advisory Committee on Immunization Practices (ACIP): evidence-based recommendations–GRADE. https://www.cdc.gov/vaccines/. Accessed October 31, 2023.
 
9. Skelly AC, Chou R, Dettori JR, et al. Noninvasive Nonpharmacological Treatment for Chronic Pain: A Systematic Review Update. Report no. 20- EHC009. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
 
10. Chou R, Wagner J, Ahmed A, et al. Treatments for Acute Pain: A Systematic Review. Comparative Effectiveness Review no. 240. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
 
11. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage 2019;27:15782013;1589.
 
12. Loder E, Weizenbaum E, Frishberg B, et al. Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache 2013;53:16512013;1659.
 
13. Gaskell H, Moore RA, Derry S, et al. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;6:CD010692.
 
14. Chou R, Hartung D, Turner J, et al. Opioid Treatments for Chronic Pain. Comparative Effectiveness Review no. 229. Rockville, MD: Agency for Healthcare Research and Quality; 2020.
 
15. Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med 2015;175:6082013;615.
 
16. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85–92.
 
17. Gomes T, Mamdani MM, Dhalla IA, et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 2011;171: 6862013;691.
 
18. Hill MV, McMahon ML, Stucke RS, et al. Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. Ann Surg 2017;265:709–714.
 
19. Hill MV, Stucke RS, McMahon ML, et al. An educational intervention decreases opioid prescribing after general surgical operations. Ann Surg 2018;267:468–472.
 
20. Mallama CA, Greene C, Alexandridis AA, et al. Patient-reported opioid analgesic use after discharge from surgical procedures: a systematic review. Pain Med 2022;23:29–44.
 
21. Frank JW, Lovejoy TI, Becker WC, et al. Patient outcomes in dose reduction or discontinuation of long-term opioid therapy: a systematic review. Ann Intern Med 2017;167:181–191.
 
22. Agnoli A, Xing G, Tancredi DJ, et al. Association of dose tapering with overdose or mental health crisis among patients prescribed long-term opioids. JAMA 2021;326:411–419.
 
23. Food and Drug Administration. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes. Accessed April 15, 2024.
 
24. Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015;350:h2698.
 
25. Krawczyk N, Mojtabai R, Stuart EA, et al. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. Addiction 2020;115:1683–1694.
 
26. Substance Abuse and Mental Health Services Administration (SAMHSA). Waiver elimination (MAT Act). https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act. Accessed November 28, 2023.